Hyperthyroidism is an endocrine condition characterized by increased synthesis and secretion of thyroid hormones by the thyroid gland, resulting in increased biological activity of T3 and T4 at tissue level. Clinically, it is one of the main causes of hypermetabolic and cardiovascular syndromes and must be distinguished from thyrotoxicosis in the broader sense, which refers to the clinical state caused by excess thyroid hormones regardless of the mechanism responsible for their production. In true hyperthyroidism, the thyroid gland is the source of the hormonal excess, whereas in other forms of thyrotoxicosis the increase in thyroid hormones results from passive release, as occurs in thyroiditis, or from exogenous intake.
The clinical impact results both from the direct effects of thyroid hormones on metabolism and thermogenesis and from their permissive role in adrenergic sensitivity and cardiovascular function. The condition may range from mild, oligosymptomatic forms to severe presentations involving arrhythmias, heart failure, and acute complications.
The epidemiology of hyperthyroidism is heterogeneous because it reflects the distribution of its main causes, which vary according to age, sex, iodine intake, and geographical setting. In areas with adequate iodine availability, thyroid autoimmunity, particularly Graves disease, accounts for a substantial proportion of cases, especially among young and middle-aged women. In settings with a higher prevalence of nodular goitre and an older population, forms caused by toxic adenoma and toxic multinodular goitre become more common. These conditions tend to develop more slowly and frequently present with a clinical phenotype dominated by cardiovascular manifestations.
The overall frequency in the general population depends on the definition used, including overt versus subclinical forms, the intensity of screening, and the laboratory thresholds adopted. Subclinical forms, defined by suppressed thyroid-stimulating hormone with free thyroxine and free triiodothyronine values within their reference ranges, are more common than overt forms and are particularly relevant in older adults, in whom they are associated with an increased risk of atrial fibrillation, heart failure, and skeletal fragility. In this setting, biological severity is strongly influenced by the degree of thyroid-stimulating hormone suppression, with a higher risk when concentrations are markedly and persistently reduced.
The main risk factors for autoimmune hyperthyroidism include a family history of autoimmune diseases, female sex, certain conditions associated with immune dysregulation, and environmental factors that modulate the immune response. Cigarette smoking is clinically relevant because it is associated with a greater risk of extrathyroidal manifestations in some autoimmune forms and influences the overall course of the disease. Physiological stress and certain reproductive events may also provide the setting in which the disease becomes clinically apparent in predisposed individuals.
For nodular forms, risk increases with age and with a history of multinodular goitre, which is often sustained by chronic stimulation of thyroid growth and by progressive clonal heterogeneity. In these patients, exposure to high iodine loads may promote the development of hyperthyroidism caused by functional autonomy, because pre-existing nodules acquire a functional advantage in iodine uptake, organification, and hormone synthesis that is no longer dependent on central regulation.
An increasingly important epidemiological category includes iatrogenic and pharmacological causes. The use of amiodarone and exposure to iodinated contrast media may precipitate hyperthyroidism in individuals with nodular autonomy or in specific settings of pre-existing thyroid dysfunction. At the same time, the increasing use of anticancer immunotherapies and agents that interfere with immune tolerance has heightened clinical attention to treatment-induced thyroid dysfunction. This most commonly takes the form of thyroiditis with a thyrotoxic phase, although more complex phenotypes may occasionally occur and require dedicated assessment.
Finally, patient vulnerability depends not only on the cause of hyperthyroidism but also on the presence of comorbidities. Structural heart disease, advanced age, osteoporosis, muscle frailty, and neurological disorders increase the clinical impact of hormonal excess because they reduce functional reserve and amplify the consequences of tachycardia, weight loss, and protein catabolism. The clinical epidemiology of hyperthyroidism is therefore closely intertwined with that of chronic diseases affecting adults and older people.
Hyperthyroidism encompasses distinct aetiopathogenetic mechanisms that share the final outcome of excess circulating thyroid hormones and increased hormone activity at tissue level. Under physiological conditions, the thyroid gland is regulated by the hypothalamic-pituitary-thyroid axis: thyroid-stimulating hormone stimulates iodide uptake, organification, thyroglobulin iodination, and the release of thyroxine and triiodothyronine. Thyroid-centred hyperthyroidism develops when this control is overridden by non-physiological stimuli or by intrinsic autonomy of thyroid tissue.
From an aetiological perspective, the most important causes include autoimmunity mediated by thyroid-stimulating hormone receptor-stimulating antibodies, nodular autonomy in the form of toxic adenoma or toxic multinodular goitre, and less common causes such as hyperthyroidism originating from ectopic thyroid tissue or functioning metastases. Autoimmunity causes activation of the thyroid-stimulating hormone receptor independently of thyroid-stimulating hormone itself, resulting in follicular hyperplasia, increased hormone synthesis, and often increased glandular vascularity. Nodular forms, by contrast, arise from areas of tissue that have acquired a functional advantage, frequently supported by alterations in cyclic adenosine monophosphate signalling or activating variants that make hormone production partially autonomous and poorly suppressible.
The pathophysiology of thyroid hormone excess is systemic. At cellular level, triiodothyronine is the main biological effector. It acts through nuclear receptors and modulates the transcription of genes involved in oxygen consumption, mitochondrial biogenesis, protein turnover, and carbohydrate and lipid metabolism. The increase in basal metabolic rate results in greater heat production and a negative energy balance, which may cause weight loss despite increased appetite, with a reduction in fat mass and, in more severe cases, muscle catabolism.
At the cardiovascular level, thyroid hormones increase heart rate and contractility and reduce peripheral vascular resistance, producing a characteristic high-output haemodynamic profile. Sensitivity to catecholamines is enhanced, promoting tachycardia, tremor, and autonomic hyperreactivity. The combination of persistent tachycardia, increased cardiac output, and reduced vascular resistance may precipitate atrial fibrillation and heart failure, particularly in predisposed individuals or those with pre-existing heart disease. Older patients may have a less overtly adrenergic presentation dominated by functional decline and arrhythmias, which can delay clinical recognition.
The musculoskeletal system is a major target. Hormonal excess accelerates bone remodelling and, when persistent, may reduce bone mineral density and increase fracture risk, especially in subclinical forms with suppressed thyroid-stimulating hormone. At muscle level, functional sarcopenia, reduced proximal strength, and easy fatigability may occur as a result of protein catabolism and altered bioenergetics. Neuromuscular function may also be impaired, with cramps, hyperreflexia, and fine tremor, which often represent early clinical signs.
Carbohydrate and lipid metabolism are also remodelled. Gluconeogenesis and glucose turnover increase, and glucose intolerance may emerge or glycaemic control may worsen in patients with diabetes. Regarding the lipid profile, increased lipoprotein catabolism tends to reduce total cholesterol and low-density lipoprotein cholesterol, but this laboratory finding should not be interpreted as protective because cardiovascular risk in hyperthyroidism is driven more by arrhythmias, heart failure, and thromboembolism than by the lipid profile.
Finally, the pathophysiology interacts with other hormonal axes and with plasma transport and binding systems. Changes in binding proteins and the use of certain treatments may alter total thyroid hormone concentrations, making measurement of free thyroxine and, when indicated, free triiodothyronine essential. This complexity explains why diagnosis is not merely a laboratory exercise but requires the reasoned integration of clinical findings, biochemistry, and aetiological context.
The clinical presentation of hyperthyroidism reflects hypermetabolism and increased adrenergic responsiveness, but it may vary considerably according to age, speed of onset, underlying cause, and comorbidities. In relatively rapidly developing forms, patients often report a noticeable change over a period of weeks or a few months, with a sensation of internal acceleration, heat intolerance, and increased sweating. In other cases, particularly slowly progressive nodular forms, symptoms emerge gradually and are attributed to stress, insomnia, or physical deconditioning.
During history taking, the most common symptoms include unintentional weight loss, increased appetite, irritability, insomnia, reduced exercise tolerance, and easy fatigability. Fine hand tremor, emotional lability, and palpitations are often early signs and correlate with the adrenergic component. Gastrointestinal disturbances with increased bowel movement frequency may occur, as may oligomenorrhoea or impaired fertility in women and reduced libido in men, because of modulation of the reproductive axes and altered sex hormone metabolism.
The physical examination requires particular attention to cardiovascular and neuromuscular signs. Sinus tachycardia, widened pulse pressure, hyperreflexia, postural tremor, and warm, moist skin are typical findings. Some patients develop proximal muscle wasting with difficulty climbing stairs or rising from a seated position, indicating thyrotoxic myopathy. Motor hyperactivity and somatic anxiety are also common and may initially lead to non-endocrine assessments unless a broad clinical perspective is maintained.
The thyroid gland may be diffusely or nodularly enlarged or may remain almost normal in size. Diffuse goitre with a thyroid bruit suggests marked glandular hyperactivity, whereas palpable nodules and an irregular gland are more consistent with nodular autonomy. However, physical examination of the thyroid is not sufficient to establish the aetiology and must be integrated with laboratory tests and imaging. Extrathyroidal signs may coexist in some autoimmune forms, whereas they are absent in many nodular forms, in which the clinical picture is dominated by arrhythmias and functional decline.
In older adults, hyperthyroidism may present as a less conspicuous clinical variant dominated by fatigue, weight loss, depression, apathy, and arrhythmias, sometimes described as an atypical or apathetic presentation. This pattern is insidious because it reduces the likelihood of timely recognition and increases the risk of cardiovascular complications before diagnosis. Thyroid function testing therefore has strategic value in the presence of new-onset atrial fibrillation, weight loss, and functional decline.
More severe forms may progress to heart failure, myocardial ischaemia caused by increased oxygen demand, accelerated bone loss, and thromboembolic vulnerability, particularly when atrial arrhythmia is persistent. In such settings, hyperthyroidism is not only an endocrine disorder but also a multiplier of systemic risk requiring multidisciplinary management and a rapid, safe therapeutic strategy.
Clinical suspicion of hyperthyroidism should arise when symptoms of hypermetabolism and autonomic overactivation are associated with consistent objective findings or characteristic complications. The combination of weight loss, heat intolerance, tremor, and palpitations is highly suggestive, but diagnosis cannot depend on a classic pattern because many presentations are incomplete or atypical. Suspicion should remain high in the presence of unexplained persistent tachycardia, insomnia resistant to usual interventions, sudden worsening of somatic anxiety, or reduced physical performance without an evident cause.
The cardiovascular setting is among the most important. The onset of atrial fibrillation, especially in the absence of an immediate cardiac explanation or in a relatively young patient, requires assessment of thyroid function. High-output heart failure and reduced exercise tolerance associated with disproportionate tachycardia are also situations in which hyperthyroidism should be considered early, because correction of hormone excess may substantially improve haemodynamic stability.
In internal medicine, hyperthyroidism should be suspected in the presence of hyperpyrexia, diarrhoea, and dehydration without a clear infectious cause, particularly when associated with tachycardia and psychomotor agitation, because these presentations may represent severe phases of thyrotoxicosis requiring urgent management. Proximal myopathy, loss of muscle mass, and skeletal fragility with low-trauma fractures may also indicate persistent hormone excess, especially in chronic subclinical forms.
Suspicion should be reinforced by predisposing factors, including a history of nodular goitre, recent exposure to a high iodine load, use of amiodarone, a family history of autoimmunity, and the presence of other autoimmune diseases. In obstetric and postpartum settings, thyroid assessment is particularly important because immunological physiology and hormonal changes may reveal thyroid dysfunction with consequences for both mother and fetus, although specific assessment according to cause and timing is required.
Finally, it is essential to consider that some patients take thyroid hormones for inappropriate indications or in an uncontrolled manner. This may mimic clinical hyperthyroidism despite having a different underlying mechanism. Clinical suspicion should therefore promptly lead to targeted investigations, avoiding delays that may transform a treatable condition into a complex clinical event, particularly in frail patients and those with heart disease.
The diagnosis of hyperthyroidism requires a rational pathway that begins with biochemical confirmation of hormone excess and proceeds to identification of the underlying cause, because treatment selection depends on the responsible mechanism. The first step is measurement of thyroid-stimulating hormone, which is typically suppressed in primary hyperthyroidism. Diagnosis, however, must not rely on thyroid-stimulating hormone alone. Free thyroxine and, when indicated, free triiodothyronine must also be measured because some presentations are characterized predominantly by increased triiodothyronine with free thyroxine still within the reference range, particularly during early disease or in certain aetiologies. The assessment must also consider treatments, acute illnesses, and changes in binding proteins that may alter total hormone concentrations and confound interpretation.
Once biochemical thyrotoxicosis has been confirmed, the differential diagnosis aims to distinguish hyperthyroidism from other forms of thyroid hormone excess. According to the American Thyroid Association guidelines for assessing the causes of thyrotoxicosis, the diagnostic pathway should integrate clinical findings, specific antibodies, thyroid function testing, and functional and structural imaging when appropriate.
Diagnostic assessment of hyperthyroidism
The distinction between hormone overproduction and passive release is crucial. In thyroiditis with a thyrotoxic phase, increased hormone concentrations result from the release of preformed hormones and uptake is typically low. In forms caused by overproduction, uptake is generally increased or otherwise inappropriate in relation to circulating hormone concentrations, with different patterns in diffuse and nodular disease. This principle guides treatment appropriateness because antithyroid agents are indicated when the thyroid gland is actively synthesizing hormones but are ineffective in blocking thyrotoxicosis caused by passive hormone release.
At the same time, clinical severity and complications, particularly cardiac complications, must be assessed. An electrocardiogram is often appropriate to identify arrhythmias and guide initial management. In patients with significant symptoms or cardiovascular comorbidities, evaluation may also include echocardiography and heart failure biomarkers because haemodynamic stabilization influences the safety and timing of aetiological treatment. Assessment of bone health and fracture risk may also be relevant in chronic or persistent subclinical forms, especially in postmenopausal women and older adults.
The diagnostic process must also consider less common causes, including exogenous thyroid hormone intake and conditions involving altered central regulation. Although primary thyroid hyperthyroidism typically presents with suppressed thyroid-stimulating hormone, rare forms of thyrotoxicosis with non-suppressed thyroid-stimulating hormone require a separate and highly specialized diagnostic pathway. When the biochemical profile is inconsistent with the expected physiology, interpretation must therefore be cautious and based on targeted reassessment and expert endocrinological consultation.
The classification of hyperthyroidism has practical value because it links pathophysiology to treatment selection and complication risk. A first distinction separates overt from subclinical hyperthyroidism. In overt hyperthyroidism, free thyroxine and/or free triiodothyronine concentrations are increased with suppressed thyroid-stimulating hormone, and the clinical presentation may be evident or variable. In subclinical hyperthyroidism, thyroid-stimulating hormone is suppressed but free hormone concentrations remain within their reference ranges. This condition may be transient or persistent and requires assessment of age-related, cardiovascular, and skeletal risk, as well as the likelihood of progression.
A second classification is aetiological and distinguishes autoimmune from autonomous nodular forms. Autoimmune forms tend to affect younger patients, frequently involve diffuse thyroid enlargement, and carry a relevant risk of fluctuations over time, including in response to treatment. Nodular forms are more typical of middle-aged and older adults and often have a more indolent but persistent course, with clinical risk dominated by arrhythmias and heart failure in vulnerable individuals.
Another clinically useful classification is based on complications and tolerance of the thyrotoxic state. Low-impact forms, in which symptoms are mild and controllable with symptomatic treatment, can be distinguished from high-risk forms associated with atrial fibrillation, haemodynamic instability, marked weight loss, muscle frailty, or major comorbidities. In these situations, a more aggressive strategy is required and the time needed to correct hormone excess becomes a prognostic determinant.
Severity also depends on the speed of progression. Rapidly developing hyperthyroidism tends to cause more overt symptoms and a greater risk of acute decompensation, whereas slowly progressive hyperthyroidism may allow some degree of clinical adaptation while causing cumulative damage to the heart and skeleton. This distinction is essential when deciding whether and how urgently to treat a subclinical form, because persistently suppressed thyroid-stimulating hormone in an older patient with heart disease is not a neutral condition even when free thyroxine and free triiodothyronine remain within their reference ranges.
Finally, classification must acknowledge that certain conditions are true endocrine emergencies and, although addressed separately, already influence clinical reasoning during the initial assessment of hyperthyroidism. In the presence of fever, altered mental status, severe diarrhoea, and cardiovascular instability, stabilization and urgent treatment of hormone excess take priority because progression may be rapid and multisystemic.
The treatment of hyperthyroidism is based on three pillars: symptomatic control, reduction of hormone excess, and targeted aetiological treatment. The strategy varies according to the cause, clinical severity, age, comorbidities, and the patient’s informed preferences because treatment options include medication, radioactive iodine therapy, and surgery. A general principle is that management must prevent cardiac complications and reduce prolonged tissue exposure to excess thyroid hormones.
Symptomatic control is often achieved with beta-blockers, which reduce tachycardia, tremor, and palpitations and improve exercise tolerance. In patients with specific contraindications, alternative treatments with similar heart rate control objectives may be considered. This intervention does not correct the underlying cause, but it is essential during the initial stages and in patients at high cardiovascular risk because it reduces the immediate impact of the thyrotoxic state.
When the thyroid gland is actively producing hormones, antithyroid agents are a cornerstone of treatment, particularly in autoimmune forms and in specific situations in which disease control is required before definitive treatment. The main objectives are to inhibit hormone synthesis and safely restore euthyroidism, thereby reducing the risk of arrhythmias and decompensation. Management requires clinical and laboratory monitoring because the intensity of inhibition must be balanced to avoid iatrogenic hypothyroidism and adjusted according to changes in the underlying disease over time.
Radioactive iodine therapy is a definitive strategy indicated in many forms of hyperthyroidism, particularly when curative treatment is desired or when recurrence or contraindications to medication are present. Its rationale is the selective destruction of hyperfunctioning thyroid tissue. This frequently results in hypothyroidism, which can be controlled with replacement therapy, but the timing and indication must be individualized. Patient selection requires specific assessments, including reproductive considerations and the presence of eye disease in autoimmune forms. In high-risk patients, thyrotoxicosis must also be clinically controlled before the procedure.
Thyroid surgery is indicated in the presence of large goitres, compressive symptoms, concomitant suspicion of malignancy, large nodules, the need for rapid resolution, or contraindications to other options. In experienced hands, surgery provides immediate control of hormone excess but requires preoperative preparation to reduce complications and careful balancing of benefits against risks involving the recurrent laryngeal nerve, parathyroid glands, and postoperative hormone management. Preparation typically includes clinical stabilization and, when appropriate, measures to reduce thyroid vascularity and symptoms through coordinated endocrinological and surgical care.
Subclinical forms require treatment decisions based on risk. Treatment may be indicated in older patients, individuals with heart disease, and those with osteoporosis or a high fracture risk even when free thyroxine and free triiodothyronine concentrations are not increased, because the objective is to reduce the risk of atrial fibrillation and fractures and to prevent progression. In younger, minimally symptomatic patients, a monitoring strategy with periodic reassessment may be appropriate, provided that a clear surveillance plan and intervention threshold are established.
Finally, treatment must include patient education and management of comorbidities. Cardiovascular assessment, evaluation of thromboembolic risk in the presence of atrial fibrillation, and prevention of bone loss are integral components of care. In the presence of acute complications or high risk, aetiological treatment must not be delayed and should be accompanied by stabilization measures that reduce exposure to the thyrotoxic state during the weeks required to achieve definitive control.
The objectives of follow-up in hyperthyroidism are to maintain euthyroidism, prevent recurrence or progression, identify complications, and manage the long-term effects of treatment. Monitoring must be structured because thyroid function may fluctuate, particularly in autoimmune forms and during adjustment of antithyroid therapy. Follow-up is more frequent during dose titration and in high-risk conditions and may be spaced out once stability has been achieved.
Laboratory follow-up includes reassessment of thyroid-stimulating hormone, free thyroxine, and, when useful, free triiodothyronine, bearing in mind that thyroid-stimulating hormone may remain suppressed for some time after normalization of free hormone concentrations. Interpretation during the early stages of treatment should therefore prioritize the clinical picture and free thyroxine and free triiodothyronine values. In patients receiving antithyroid therapy, clinical monitoring must include early recognition of clinically important adverse effects and verification of adherence and understanding of the treatment plan, because dosing errors and self-directed discontinuation are common causes of instability.
Cardiovascular surveillance is central in older patients and in those with arrhythmias. Persistent or recurrent tachycardia, the onset of palpitations, and the presence of atrial fibrillation require dedicated assessment, while thromboembolic risk must be managed through an integrated approach based on the individual patient profile. Some arrhythmias may persist even after correction of hyperthyroidism, and cardiological treatment decisions must be coordinated with endocrine stabilization.
Follow-up must also address the musculoskeletal system. In prolonged or persistent subclinical forms, fracture risk and, when indicated, bone mineral density should be assessed, particularly in postmenopausal women and older adults. Recovery of muscle mass and function requires time after hormone normalization, and interventions involving nutrition and physical activity must be calibrated according to cardiovascular status and the degree of deconditioning.
After radioactive iodine treatment or surgery, follow-up focuses on identifying and treating possible hypothyroidism. This is an expected and manageable outcome with replacement therapy, but adequate monitoring is required to avoid prolonged periods of unrecognized hypothyroidism. The quality of follow-up also depends on continuity of care and on adapting treatment over time according to changes in body weight, age, pregnancy status, comorbidities, and the use of interfering treatments.
Finally, in forms that may remit or recur, follow-up should include an explicit plan for recognizing early symptoms and arranging timely testing. An informed patient and a clearly defined surveillance pathway reduce the risk of delayed recognition of recurrence and cardiovascular complications, which are the main determinants of adverse outcomes in uncontrolled disease.
The prognosis of hyperthyroidism is generally favourable when diagnosis is timely and treatment is appropriate to the underlying cause and the patient’s risk profile. Most systemic manifestations regress after euthyroidism is restored, but the speed and completeness of recovery depend on the duration of hormone exposure, clinical severity, and the presence of pre-existing organ damage. In younger patients without comorbidities, hormone normalization often results in complete functional recovery, whereas residual risk may remain significant in older patients and those with heart disease even after endocrine control has been achieved.
The most clinically important complications are cardiovascular. Atrial fibrillation is one of the most frequent and consequential manifestations, increasing thromboembolic risk and the likelihood of heart failure. Persistent tachycardia may also contribute to tachycardia-induced cardiomyopathy and functional decline, particularly when hyperthyroidism remains unrecognized for several months. In patients with ischaemic heart disease, increased myocardial oxygen demand may precipitate angina and instability, making correction of hormone excess a clinical priority.
The skeletal and muscular systems represent a second major area of complications. Increased bone remodelling and reduced bone mineral density may lead to osteoporosis and low-trauma fractures, with a higher risk in persistent subclinical forms and older adults. Thyrotoxic myopathy causes reduced strength and increases the risk of falls, creating a vicious cycle between muscle frailty and fracture risk. Hormone normalization improves these abnormalities, but restoration of muscle mass may be slow and may require rehabilitation and nutritional intervention when indicated.
Metabolic complications include worsening glycaemic control in patients with diabetes and weight loss accompanied by protein depletion. In frail patients and those with chronic diseases, thyrotoxicosis may accelerate sarcopenia and reduce immunometabolic resilience, increasing the risk of adverse events during infections or hospital admissions. Neuropsychiatric effects, including anxiety, insomnia, and irritability, may impair treatment adherence and quality of life even after hormone concentrations have normalized, making integrated assessment useful in patients with persistent symptoms.
Regarding treatment-related complications, prognosis also depends on the choice and management of therapy. Antithyroid agents require surveillance for clinically important adverse events, radioactive iodine therapy requires accurate follow-up to prevent unrecognized hypothyroidism, and surgery requires expertise and postoperative monitoring. Within a well-structured care pathway, these complications are preventable or manageable and should not represent an obstacle to correcting hormone excess when the latter exposes the patient to greater systemic risks.
Overall, hyperthyroidism is a condition with a major clinical impact, particularly because of its cardiovascular consequences and the complications caused by chronic exposure to excess thyroid hormones. Its outcome is nevertheless generally favourable when the aetiological assessment is correct and treatment is individualized, timely, and accompanied by continuous monitoring.